Browse the evidence

Structured dietary weight-loss maintenance (WLM) is well accepted by participants.

Practitioners can confidently implement these dietary strategies knowing they are well received.

Semaglutide, tirzepatide, and retatrutide achieve placebo-subtracted bodyweight loss of up to 10.8%, 17.8%, and 22.1%, respectively, in adults after 48-72 weeks.

These medications can significantly aid in weight loss for adults with obesity.

Semaglutide reduces body mass index mean by up to 16.7% in adolescents with obesity after 68 weeks.

Semaglutide can be effective for weight management in adolescents with obesity.

Tirzepatide likely results in a greater percentage reduction in body weight from baseline (mean difference -16.03, 95% CI -18.91 to -13.14) compared to placebo.

Practitioners can consider tirzepatide as an effective option for weight loss in adults with obesity.

Tirzepatide likely increases the number of people achieving a 5% weight reduction (risk ratio 3.60, 95% CI 2.44 to 5.30) compared to placebo.

Tirzepatide may be particularly effective for helping patients achieve significant weight loss goals.

At 5-6 months, the mean weight reduction was 7.9%, with 56% of participants achieving more than 5% weight loss.

Phentermine/topiramate ER can be effective for weight loss in obese patients.

At 12 months, patients who persisted in treatment experienced an average weight loss of 9.6%, with 65% surpassing a 5% weight loss.

Long-term adherence to treatment can lead to significant weight loss.

Muscle mass can be significantly preserved by integrating resistance training, adequate protein intake, and body composition monitoring into weight-loss treatment programs.

Incorporating resistance training and proper nutrition can help maintain muscle mass during weight loss efforts.

Retatrutide administered at a 12 mg dosage resulted in significant reductions in body weight, body mass index, and waist circumference.

Practitioners can consider retatrutide as an effective treatment option for obesity.

A higher percentage of patients receiving retatrutide achieved weight losses of ≥5%, 10%, 15%, and 20% compared to placebo.

Retatrutide may be particularly effective for patients aiming for significant weight loss.

Efsubaglutide Alfa produced a mean weight reduction of 7.16% versus 0.86% with placebo.

Efsubaglutide Alfa may be an effective treatment option for weight loss in individuals with obesity or overweight.

82.5% of Efsubaglutide-treated participants achieved ≥5% weight loss.

A significant proportion of individuals treated with Efsubaglutide Alfa can expect to achieve clinically meaningful weight loss.

Cagrisema produced significantly greater percentage weight loss than semaglutide with a mean difference of -7.47% (95% CI: -10.58, -4.36; p < 0.001).

Cagrisema may be a more effective option for weight loss in obese patients compared to semaglutide.

Cagrilintide monotherapy weight loss was comparable to semaglutide.

Cagrilintide may be a viable alternative to semaglutide for weight management in obese patients.

Cagrisema is safe and has a comparable side effect profile to semaglutide.

Cagrisema can be considered a safe option for weight management in obese patients.

Meal replacements (MRs) led to a greater reduction in body weight by -1.38 kg compared to conventional food-based weight loss diets.

Incorporating meal replacements can be an effective strategy for weight loss in individuals at risk of metabolic syndrome.

MRs resulted in a reduction in body mass index (BMI) by -0.56 kg/m2 compared to conventional diets.

Using meal replacements can help reduce BMI in at-risk populations.

Incorporating MRs into a weight loss intervention leads to reductions in LDL-c by -0.18 mmol/L and non-HDL-c by -0.17 mmol/L.

Meal replacements can improve lipid profiles in individuals at risk of metabolic syndrome.

Retatrutide treatment for 48 weeks resulted in a least-squares mean percentage change in body weight of -24.2% in the 12 mg group compared to -2.1% in the placebo group.

Retatrutide may be an effective treatment option for significant weight loss in adults with obesity.

A weight reduction of 5% or more occurred in 100% of participants who received 8 mg of retatrutide.

The 8 mg dose of retatrutide is highly effective for achieving at least a 5% weight loss in this population.

Various types of physical activity enhance health and glycemic management in people with type 2 diabetes.

Practitioners should encourage a variety of physical activities to improve health and glycemic control in patients with type 2 diabetes.

People with type 2 diabetes should engage in physical activity regularly and reduce sedentary time.

Encourage patients to incorporate regular physical activity and minimize sedentary behavior.

Exercise timing may maximize glucose-lowering effects.

Consider advising patients on the timing of exercise to enhance glucose management.

Various types of physical activity enhance health and glycemic management in people with type 2 diabetes.

Practitioners should encourage a variety of physical activities to improve health and glycemic control in patients with type 2 diabetes.